Semax and Selank keep showing up together online. Almost like a package deal.
Both came out of the same era of Russian neuropeptide research, built largely through the Institute of Molecular Genetics and related Russian Academy of Sciences groups.
Both get called “nootropics.” Both have a short, easy name.
Underneath that, they’re studied for pretty different things.
Semax comes from a fragment of ACTH, a stress-response hormone, and gets researched mainly around BDNF, brain-derived neurotrophic factor. Selank comes from a totally different parent molecule, tuftsin, an immune-signaling peptide, and gets researched mainly around anxiolytic-type behavior, GABA signaling, and immune gene activity.
Related research tradition. Different starting molecules. Different primary research questions.
Structurally, though, they’re not as far apart as that makes them sound. Both are seven-amino-acid peptides. Same length, same ending, different first four building blocks.
That shared structure is genuinely useful for comparing the two, and most casual descriptions leave it out entirely.
This guide covers what Semax actually is, what Selank actually is, what the two genuinely have in common, and how they compare when people talk about them as a pair.
See Certified Peptide Solutions’ Semax and Selank research compounds.
What Is Semax?
Semax is a synthetic heptapeptide, commonly labeled in the literature as an ACTH(4-10) analog. Structurally, it’s the ACTH(4-7) sequence, Met-Glu-His-Phe, with a Pro-Gly-Pro tail attached.
Full sequence: Met-Glu-His-Phe-Pro-Gly-Pro.
Unlike full ACTH, Semax doesn’t carry ACTH’s classic hormonal, stress-response activity, according to the literature.
BDNF is one of the best-characterized research threads around Semax. Animal research has found increased BDNF protein alongside changes in TrkB signaling. Separate work found region-specific changes in both BDNF and NGF, nerve growth factor, gene expression.
That thread has real numbers behind it, not just general association. One rat hippocampus study found Semax linked to a 1.4-fold increase in BDNF protein and a 1.6-fold increase in TrkB phosphorylation, plus increases in BDNF and TrkB mRNA.
Separate research found specific, reversible Semax binding sites in rat basal forebrain, with an average binding affinity of 2.4 nM, alongside increased BDNF protein in that same tissue.
Worth being precise is that binding-site finding doesn’t confirm a specific Semax receptor. It does make Semax a well-characterized research material for neurotrophin and TrkB signaling work specifically.
BDNF isn’t the whole Semax story, though.
Broader gene-expression research, including a 2024 RNA-sequencing study in rat frontal cortex, found effects spanning hundreds of genes after Semax administration.
Researchers studying Semax are pretty upfront that its complete mechanism isn’t pinned down yet. Not one clean pathway.
Semax’s research history goes beyond animal and cell-culture work too.
It’s a registered pharmaceutical product in Russia, sold there as 0.1% and 1% nasal drops, studied in Russian clinical literature tied to cerebral circulation and stroke recovery, including research on plasma BDNF and rehabilitation outcomes in post-stroke patients.
Russian registration isn’t the same thing as FDA approval, and it doesn’t mean the international clinical picture is settled.
FDA reportedly reviewed Semax-related bulk substances in 2026 and concluded the evidence was insufficient to support effectiveness for cerebral ischemia, migraine, or trigeminal neuralgia, also finding the clinical safety information insufficiently characterized.
Semax carries no FDA approval and no approved use anywhere in the United States.
What Is Selank?
Selank is a synthetic heptapeptide built around tuftsin, a naturally occurring immune-regulatory tetrapeptide. Tuftsin corresponds to residues 289 through 292 of the CH2 domain of the IgG heavy chain.
Selank’s full sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro.
That’s the tuftsin sequence, Thr-Lys-Pro-Arg, with the same Pro-Gly-Pro tail found on Semax attached.
Selank’s research covers more ground than a single “anxiolytic” label suggests. Anxiolytic-type behavioral research is a real, substantial chunk of the literature, run through standard rodent behavioral models used across anxiolytic pharmacology generally.
A second mechanistic thread involves GABA signaling. One rat frontal-cortex study measured 84 neurotransmission-related genes and found significant changes in 45 of them one hour after Selank exposure, dropping to 22 genes by the three-hour mark.
The researchers reported overlap between Selank’s effects and GABA-associated expression patterns. A separate radioligand study found altered GABA binding, which the researchers described as a form of positive modulation.
That picture isn’t perfectly consistent, though. At least one cell-based study found Selank alone didn’t change a tested GABA-related gene panel. It only showed an effect combined with GABA or another compound. These findings point toward a research direction, not a locked-in mechanism.
Selank’s immune-signaling research gets more specific than most summaries suggest, too. A mouse-spleen study looked at 84 inflammation-related genes and found significant expression changes in 34 of them after Selank exposure. Separate research found changes in chemokine- and cytokine-related gene expression.
These are preclinical gene-expression findings. Not evidence of a demonstrated immune benefit in people.
Selank’s literature also includes small human clinical studies out of Russia, including head-to-head comparisons with established anxiolytic drugs in people with anxiety- and somatoform-spectrum diagnoses.
That human evidence is real. It’s also limited in scale, mostly Russian, and nowhere close to the large, independently replicated, internationally distributed trials that would support treating Selank as an established therapy in the US.
Like Semax, Selank is a registered pharmaceutical product in Russia, currently sold there as a 0.15% nasal drop. That registration doesn’t change Selank’s status here: a research compound, evaluated under research-use framing only, with no FDA approval anywhere in the United States.
What Do Semax and Selank Actually Have in Common?
Beyond the shared research tradition, Semax and Selank have real structural and biochemical overlap worth calling out directly.
Both are seven-amino-acid peptides. Both end in the same Pro-Gly-Pro tripeptide. Both trace back to overlapping Russian research groups, especially the Institute of Molecular Genetics and related Russian Academy of Sciences teams.
That’s part of why so much of the mechanistic and clinical literature for both compounds shares the same authors and institutions.
There’s direct experimental overlap too. One study tested Semax and Selank together and found both compounds inhibited enkephalin-degrading enzymes in human serum, dose-dependently, with Semax somewhat more potent than Selank under the tested conditions.
That doesn’t make enzyme inhibition either compound’s main mechanism. It does mean these two aren’t complete biochemical opposites, even with their dominant research questions pointing in different directions: BDNF and neurotrophin signaling for Semax, anxiolytic and immune research for Selank.
The shared PGP tail isn’t just structural filler, either.
Separate research examining PGP on its own, apart from either full compound, found it produced measurable transcriptomic changes in a rat ischemia model. Worth knowing before assuming that tail is inert scaffolding stuck onto the “real” sequence in either peptide.
Evidence quality is worth separating from evidence volume here too. Both compounds have a lot of indexed literature, but a big share of the mechanistic and clinical work traces back to the same overlapping Russian research groups that developed them.
Independent research exists, including Italian chemistry work on Semax specifically, but replication across unrelated international labs stays thinner than the raw publication count would suggest.
How Do Semax and Selank Compare in Research Focus?
| Semax | Selank | |
| Sequence | MEHFPGP | TKPRPGP |
| Length | 7 amino acids | 7 amino acids |
| Parent sequence | ACTH(4-7) | Tuftsin (TKPR) |
| Shared structural feature | C-terminal Pro-Gly-Pro | C-terminal Pro-Gly-Pro |
| Strongest research thread | BDNF/TrkB and broader neurotrophin signaling | Anxiolytic-type behavior and GABA-related signaling |
| Additional research | NGF, ischemia models, broad transcriptomic gene-expression changes | Immune and inflammation-related gene expression |
| Human literature | Some Russian clinical studies | Some Russian clinical studies |
| Russian status | Registered nasal medicine (0.1% / 1%) | Registered nasal medicine (0.15%) |
| US status | Not FDA-approved | Not FDA-approved |
Semax and Selank differ a lot in their dominant research questions. They’re not mechanistic opposites, though. Both share a structural feature, and in at least one study, a biochemical effect too.
What actually separates them is where research attention has piled up: neurotrophin and cognitive-adjacent signaling for Semax, anxiolytic and immune signaling for Selank.
For researchers, the practical distinction comes down to the endpoint being studied. Semax has a stronger experimental track record around neurotrophin expression: BDNF, NGF, Trk-family signaling specifically.
Selank has its own distinct track record around GABA-related neurotransmission and immune/inflammation gene expression.
Neither one is broadly “better.” Compound selection is part of experimental design here, not an interchangeable coin flip between two similarly named products.
Sourcing Semax and Selank for Research
Identity confirmation matters more than usual for this pair. Both Semax and Selank are seven-residue peptides ending in the same Pro-Gly-Pro tail. Their first four residues are different: MEHF for Semax, TKPR for Selank.
A chromatographic purity percentage alone can’t confirm the dominant peak is actually the intended sequence and not the other one. That’s exactly why identity-specific testing matters here, right alongside purity data.
Sequence identity is only part of the picture, though. FDA’s 2026 review of Semax-related bulk substances reportedly flagged peptide-related impurities from incomplete coupling, truncations, and side reactions, plus peptide aggregates and synthesis-process impurities.
FDA also apparently found gaps in publicly available Semax certificates of analysis: missing impurity data, missing aggregation information.
For researchers comparing suppliers, that makes the underlying documentation worth more than a headline purity number on its own.
Regulatory review has also specifically flagged aggregation and peptide-related impurities as relevant concerns for Semax- and Selank-related compounded substances generally.
A useful research COA should tell you what the material actually is, and how clean the tested lot is. Not just one number standing in for both.
Certified Peptide Solutions’ guide to reading a peptide certificate of analysis covers how to evaluate that documentation for any research peptide, Semax and Selank included.
Frequently Asked Questions
What is Semax?
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It combines the ACTH(4-7) fragment with a Pro-Gly-Pro tail. Semax research has focused mainly on BDNF and other neurotrophin-related signaling, along with learning, memory, and gene-expression changes in experimental models.
What is Selank?
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is derived from the immune-related peptide tuftsin and includes a Pro-Gly-Pro tail. Selank research has examined anxiolytic-type behavior, GABA-related signaling, gene expression, and immune-associated pathways.
How do Semax and Selank compare in research focus?
Semax and Selank are studied for different biological questions. Semax research focuses more heavily on BDNF, neurotrophin signaling, learning, and memory. Selank research focuses more on anxiolytic-type behavior, GABA-related signaling, and immune pathways. Both share a Pro-Gly-Pro tail but have different parent sequences.
Are Semax and Selank the same compound?
No. Semax and Selank are different peptides with different amino-acid sequences and parent molecules. Semax is derived from ACTH(4-7), while Selank is derived from tuftsin. They are structurally related in one respect, however, because both end with the same Pro-Gly-Pro sequence.
Are Semax or Selank FDA-approved?
No. Semax and Selank aren’t FDA-approved drugs and don’t have FDA-approved uses in the United States. Both have been registered as pharmaceutical products in Russia, but that regulatory status doesn’t make either compound FDA-approved or change the status of research-use products sold in the U.S.
What research models are used to study Semax and Selank?
Semax research commonly uses rodent learning and memory models alongside neurotrophin and gene-expression measurements. Selank research commonly uses behavioral models of anxiety, GABA-related assays, and immune-signaling measurements. These preclinical models can show biological effects under experimental conditions, but they don’t by themselves establish the same outcomes in humans.
For laboratory research only. Not for human or veterinary use. Not for human consumption. No therapeutic, diagnostic, dosing, or treatment claims are made. See Certified Peptide Solutions’ Research Purposes Only policy for full research-use guidance.